Gotham Asset Management LLC Purchases 63,231 Shares of Bruker Co. (NASDAQ:BRKR)

Gotham Asset Management LLC lifted its position in Bruker Co. (NASDAQ:BRKR) by 146.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 106,324 shares of the medical research company’s stock after acquiring an additional 63,231 shares during the quarter. Gotham Asset Management LLC owned 0.07% of Bruker worth $6,233,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in BRKR. Eagle Bay Advisors LLC lifted its holdings in shares of Bruker by 2,324.1% in the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock worth $41,000 after acquiring an additional 674 shares during the last quarter. UMB Bank n.a. lifted its holdings in shares of Bruker by 37.5% in the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock worth $53,000 after acquiring an additional 248 shares during the last quarter. Quadrant Capital Group LLC lifted its holdings in shares of Bruker by 18.2% in the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company’s stock worth $75,000 after acquiring an additional 196 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Bruker by 41.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,330 shares of the medical research company’s stock worth $78,000 after acquiring an additional 390 shares during the last quarter. Finally, Parvin Asset Management LLC bought a new stake in shares of Bruker in the 4th quarter worth about $112,000. Institutional investors own 79.52% of the company’s stock.

Bruker Trading Down 3.8%

NASDAQ BRKR opened at $38.74 on Wednesday. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The company has a market capitalization of $5.87 billion, a price-to-earnings ratio of 50.97, a price-to-earnings-growth ratio of 2.16 and a beta of 1.23. The company’s 50-day simple moving average is $40.94 and its two-hundred day simple moving average is $50.89. Bruker Co. has a one year low of $34.10 and a one year high of $79.78.

Bruker (NASDAQ:BRKR) last posted its earnings results on Wednesday, May 7th. The medical research company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.01. The business had revenue of $801.40 million for the quarter, compared to the consensus estimate of $763.83 million. Bruker had a net margin of 3.36% and a return on equity of 21.01%. The company’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.53 EPS. Equities analysts forecast that Bruker Co. will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Monday, March 17th were given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date was Monday, March 17th. Bruker’s dividend payout ratio (DPR) is 38.46%.

Wall Street Analyst Weigh In

Several research firms recently commented on BRKR. Barclays reduced their price target on shares of Bruker from $50.00 to $46.00 and set an “overweight” rating on the stock in a research note on Thursday, May 8th. Wells Fargo & Company reduced their price target on shares of Bruker from $75.00 to $60.00 and set an “overweight” rating on the stock in a research note on Thursday, April 17th. Citigroup reduced their price target on shares of Bruker from $75.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, April 7th. Guggenheim reaffirmed a “buy” rating on shares of Bruker in a research note on Monday, February 24th. Finally, UBS Group reduced their price target on shares of Bruker from $57.00 to $45.00 and set a “neutral” rating on the stock in a research note on Thursday, May 8th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $60.10.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.